The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies

Cubie, Heather A., Moore, Catherine, Waller, Michael and Moss, Sue (2005) The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies. Journal of Clinical Virology, 33 4: 287-292. doi:10.1016/j.jcv.2004.12.011

Author Cubie, Heather A.
Moore, Catherine
Waller, Michael
Moss, Sue
Title The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies
Journal name Journal of Clinical Virology   Check publisher's open access policy
ISSN 1386-6532
Publication date 2005-08
Sub-type Article (original research)
DOI 10.1016/j.jcv.2004.12.011
Volume 33
Issue 4
Start page 287
End page 292
Total pages 6
Place of publication Amsterdam, Netherlands
Publisher Elsevier
Language eng
Subject 010402 Biostatistics
111706 Epidemiology
Abstract Background: Cervical screening by cytology is effective but lacks sensitivity. The addition of human papillomavirus (HPV) testing can improve the effectiveness of screening for early identification of cervical disease. As HPV testing represents a new technology, a quality assurance (QA) programme is necessary to confirm the accuracy of results. Objective: Our main objective was to design a QA programme for use in the English NHS liquid-based cytology (LBC) and HPV Cervical Screening Pilot Study. Our second objective was to use the knowledge gained to design a QA scheme for future general use within cervical screening and HPV testing programmes. Study design: Four elements were included in the programme: provision of clinical samples of known HPV status for internal quality control (IQC), distribution of panels of unknown samples for external quality assessment (EQA), resubmission of aliquots of samples to the reference laboratory for repeat testing and resubmission to reference laboratory to check for transport problems. Three sites took part in the QA programme using PreservCyt® medium and ThinPrep® for LBC preparation. The assay used at test sites was HPV hybrid capture (hc2) while the quality assurance laboratory used a combination of hc2, in-house HPV polymerase chain reaction (PCR) tests and HPV linear array (LA). Results: Four negative, three low positive and 11 positive pools were used in 22 distributions of IQC samples. Seven distributions each of five ‘unknown’ EQA samples were sent out. Over 400 samples underwent repeat testing. Discrepant samples were further assessed to provide an explanation. Inter- and intra-laboratory consistency was high as measured by Kappa statistics and 96% agreement for EQA samples was obtained. Conclusions: The validity of the QA programme was established and reproducibility in different lab settings was reassuring. These results support the use of hc2 as a potential screening test in diagnostic laboratories. The need for robust quality assurance of HPV testing in cervical screening programmes was confirmed and lessons learnt from this pilot study will be incorporated in future schemes.
Keyword Virus diseases
Quality assurance
Cervical screening
Human papillomavirus
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
ERA 2012 Admin Only
Centre for Military and Veterans' Health Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 13 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 03 Apr 2009, 10:22:35 EST by Ms Karen Naughton on behalf of Centre for Australian Military & Veterans' Health